Michael P. Randall

Internal Medicine

601 N Caroline St Ste 7008
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS).

CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS).

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS).

CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS).

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 01, 2026

Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.

Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.

Journal: Haematologica

Published: March 17, 2026

Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity conditioning allogeneic bone marrow transplantation with post-transplantation cyclophosphamide.

Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity conditioning allogeneic bone marrow transplantation with post-transplantation cyclophosphamide.

Journal: Bone marrow transplantation

Published: April 14, 2024

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy.

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy.

Journal: Cancers

Published: June 30, 2023

The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances.

The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances.

Journal: Cancer journal (Sudbury, Mass.)

Published: May 17, 2023

BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.

BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.

Journal: Journal of the National Cancer Institute

Published: March 10, 2023

Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival.

Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival.

Journal: Journal of the National Cancer Institute

Published: March 09, 2023

BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.

BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.

Journal: bioRxiv : the preprint server for biology

Published: February 13, 2023

Germline pathogenic variants in 786 neuroblastoma patients.

Germline pathogenic variants in 786 neuroblastoma patients.

Journal: medRxiv : the preprint server for health sciences

Published: February 07, 2023

Tafasitamab at the blood-brain barrier.

Tafasitamab at the blood-brain barrier.

Journal: British journal of haematology

Published: December 15, 2022

The Simons Observatory: A large-diameter truss for a refracting telescope cooled to 1 K.

The Simons Observatory: A large-diameter truss for a refracting telescope cooled to 1 K.

Journal: The Review of scientific instruments

Published: June 01, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026